Lotte Biologics, Asimov unveil next-gen CDO model that cuts DNA-to-GMP timeline to 8.5 months

Lotte Biologics has teamed up with US biotech firm Asimov to unveil a next-generation contract development organization (CDO) ...
GEN

Exogenus Therapeutics Taps Lonza to Develop a GMP-Compliant Process for Lead Exosome-Based Candidate

Exogenus Therapeutics and Lonza agreed to collaborate on the development of Exo-101, Exogenus’ exosome-based lead candidate. The company specializes in the development of therapeutics based on ...

Matica Bio, VaxDome partner on antiviral hybrid vaccine development

Matica Biotechnology, the US contract development and manufacturing organization subsidiary of CHA Biotech, has partnered ...
Yahoo Finance

WuXi Biologics' 25th Drug Substance Facility Completes First GMP Production, Manufacturing Process Execution with Zero Deviations

SHANGHAI, June 24, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG17 drug substance ...

Intravacc Highlights Four Integrated Vaccine Development Platforms for CDMO Partners

Intravacc offers four complementary vaccine development platforms: bacterial vaccines, viral vaccines, conjugate vaccines, and E.coli expressed ...
FierceBiotech

Beyond Rigid Platforms: Adaptive Adenoviral Platform De-Risks Development to GMP

An adenoviral process that works for one construct can fail with the next. A harvest step optimized in development can erode yield at scale, and an early analytical method can stall a program at ...
GEN

Consider Cell Therapy GMP Manufacturing Early in Development

Small biotechs in early development of cell therapies are often surprised by the strictness of commercial manufacturing standards. That’s the view of Luděk Sojka, PhD, CEO of contract developer and ...

Onco-Innovations Initiates Polymer Process Development and Characterization Program for ONC010

VANCOUVER, BC / ACCESS Newswire / June 30, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce, further to its news ...